EGFR and cancer: A retrospective study revealed that not all EGFR mutations have a similarly grim prognosis for ICI efficacy: while exon 19 mutations associated with poorer ICI responses, L858R mutations showed no difference compared to EGFR wild-type cancers and were linked to higher TMB [59].